The Science
Our work is grounded in published research, mechanistic understanding, and rigorous clinical data collection.
Research Areas
Rapamycin & mTOR Inhibition
Dose optimisation, long-term safety, and outcome tracking in companion animals treated with rapamycin.
- Individualised dosing protocols based on body composition and metabolic markers
- Long-term monitoring of immunological, metabolic, and cardiac function
- Correlation between rapamycin dose, biomarker changes, and healthspan outcomes
AAV Gene Therapy
Clinical application of AAV-mediated gene therapy for healthspan extension and disease prevention.
- Follistatin AAV for muscle preservation and metabolic health
- Klotho AAV for kidney function and cognitive protection
- TERT AAV for cellular rejuvenation and tissue repair
Stem Cell Therapy
Autologous and allogeneic cell therapy for regenerative medicine and immune modulation.
- Adipose-derived mesenchymal stem cells for osteoarthritis and tissue repair
- NK cell therapy for cancer immunotherapy
- GMP protocols and quality control for clinical-grade cell products
Biomarker Science
Development of canine-specific biomarker panels and individualised reference ranges.
- Longitudinal biomarker tracking and age-related decline patterns
- AI-powered analysis for individualised reference ranges
- Correlation between biomarker changes and clinical outcomes
Evidence Base
Published Research
All interventions are based on peer-reviewed research from veterinary and comparative medicine literature.
Mechanistic Understanding
We understand the biological pathways targeted by each intervention and monitor for expected effects.
Clinical Data
We systematically collect outcome data to validate protocols and contribute to the evidence base.
Continuous Learning
Protocols evolve as new research emerges. We adapt based on evidence, not dogma.
Publications & Case Studies
We are committed to publishing our clinical data and contributing to the scientific literature.
Scientific Advisory Board
We work with leading researchers in longevity science, gene therapy, and veterinary medicine.
Advisory Board Member
Expertise in veterinary longevity medicine and translational research.
Advisory Board Member
Expertise in gene therapy and regenerative medicine.
Data Transparency
We are committed to open science and transparent reporting of outcomes.
Public Data Sharing
Anonymised outcome data will be made publicly available to advance the field.
Protocol Documentation
Detailed intervention protocols are documented and shared with the veterinary community.
Adverse Event Reporting
All adverse events are tracked, reported, and analysed to improve safety.
Research Collaboration
We actively collaborate with academic institutions and research groups.